Silexion Therapeutics Corp reported financial results for Q2 2025 and highlighted recent milestones. Their second-generation drug SIL204 showed promising results in pancreatic, colorectal, and lung cancer models, with up to 94% inhibition in KRAS G12D mutations. Phase 2/3 trials for SIL204 targeting pancreatic cancer are set for 2026.

A strategic partnership with Catalent for formulation development was announced. Silexion aims to combat primary tumors and metastases. Regulatory submissions for Phase 2/3 trials are planned for late 2025 and early 2026. The company also maintained its Nasdaq listing after a reverse share split in July 2025.

Financially, Silexion’s cash position improved to $3.5 million by June 2025 from $1.2 million in December 2024. Operating expenses for Q2 2025 rose to $2.3 million, leading to a net loss of $2.5 million. Total net loss for the first six months of 2025 was $4.2 million, reflecting increased expenses related to being a public company.

Read more at GlobeNewswire: Silexion Therapeutics Reports Second Quarter 2025 Financial